新领导力推动生物技术和人工智能初创企业增长New leadership drives growth in biotech and AI startups

Biotech experts Mark Pruzanski and Andrew Roberts have stepped into new roles as Chief Executive Officers of Alentis and InterAx to support and accelerate the companies’ clinical developments. At Artificialy, co-founder Luca Gambardella is now the CEO. His role includes strengthening the company’s position in the Ticino region and across Switzerland..

生物技术专家马克·普鲁赞斯基和安德鲁·罗伯茨已分别担任Alentis和InterAx的首席执行官，以支持和加速这些公司的临床开发。在Artificialy，联合创始人卢卡·甘巴德拉现在担任首席执行官，他的职责包括加强公司在提契诺地区及整个瑞士的地位。

Mark Pruzanski

马克·普鲁赞斯基

, a renowned physician entrepreneur is the newly appointed Chief Executive Officer of

，一位著名的企业家医生，是新任命的首席执行官

Alentis

阿伦蒂斯

, a clinical-stage biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-1 for fibrosis and oncology indications. Pruzanski boasts more than 30 years of experience in the life sciences industry. Most recently, he served as Chairman and CEO of Versanis Bio where he spearheaded the development of a novel approach to obesity therapy until the company’s acquisition by Eli Lilly and Company.

，一家处于临床阶段的生物技术公司，率先开发针对claudin-1的一流抗体和抗体药物偶联物（ADC），用于纤维化和肿瘤适应症。Pruzanski在生命科学行业拥有超过30年的经验。最近，他担任Versanis Bio的董事长兼首席执行官，在那里他领导了一种针对肥胖症治疗的创新方法的开发，直到公司被礼来公司收购。

Prior to joining Versanis, he founded and was the longstanding CEO of Intercept Pharmaceuticals, where he successfully steered the molecule obeticholic acid from discovery to a globally marketed product in chronic liver disease. Pruzanski is currently a member of the Board of Directors of several biotech companies and the Biotechnology Innovation Organization (BIO)..

在加入Versanis之前，他创立了Intercept Pharmaceuticals并长期担任首席执行官，成功将奥贝胆酸从发现阶段发展为全球上市的慢性肝病治疗产品。普鲁赞斯基目前是多家生物技术公司和生物技术创新组织（BIO）的董事会成员。

InterAx Biotech under new leadership

InterAx生物技术公司在新领导层下

Also, joining the startup biotech scene is

此外，加入初创生物技术领域是

Andrew Roberts

安德鲁·罗伯茨

, the new CEO of

，新任首席执行官

InterAx

InterAx

, an AI-driven drug discovery company with a first-in-class platform that uncovers how drugs work at a deeper physiological level. Roberts brings 20+ years of end-to-end biopharmaceutical R&D and portfolio leadership across Big Pharma and biotech organizations such as Novartis, Sandoz and Biogen Idec.

是一家人工智能驱动的药物发现公司，拥有一个一流平台，可以更深入地揭示药物在生理层面的作用机制。罗伯茨在大型制药公司和生物技术组织（如诺华、山德士和百健艾迪克）拥有 20 多年的端到端生物制药研发和投资组合领导经验。

He has served as Chief Portfolio Officer at Alvotech and was Partner at Thaxton Philip Consulting. Roberts has deep experience in drug development across a variety of therapeutic areas, indications and phases, having worked on over 40 development programs from translational medicine through to post-marketing studies.

他曾担任Alvotech的首席投资组合官，并且是Thaxton Philip Consulting的合伙人。罗伯茨在多种治疗领域、适应症和阶段的药物开发方面拥有深厚的经验，曾参与过40多个从转化医学到上市后研究的开发项目。

His contributions have led to the approval of over 15 new products..

他的贡献促成了超过15种新产品的批准。

In his new role, he will accelerate the InterAx’s transition from a drug discovery technology pioneer into a developer of safer and more efficacious GPCR-class drugs while maturing its transformative drug discovery platform across multiple therapeutic areas. Roberts will guide InterAx’s next phase of growth: maximizing the capabilities of its technology platform to generate a robust portfolio of drug candidates with an initial focus on metabolic diseases.

在他的新职位上，他将加速InterAx从药物发现技术先驱向更安全、更有效的GPCR类药物开发者转型，同时在多个治疗领域完善其变革性的药物发现平台。罗伯茨将引领InterAx的下一阶段增长：最大化利用其技术平台的能力，构建强大的候选药物组合，初期聚焦于代谢类疾病。

Key priorities include fundraising, advancing lead programs towards clinical development and strategically expanding the pipeline..

关键优先事项包括筹集资金、推动主要项目向临床开发迈进，以及战略性地扩展产品管线。

Artficialy’s co-founder becomes CEO

Artficialy的联合创始人成为首席执行官

With its team of 40 employees operating between Lugano and Zurich,

凭借其在卢加诺和苏黎世之间运营的40名员工的团队，

Artificialy

人工地

is an Artificial Intelligence company designing and delivering AI solutions that are impactful, transparent, and tailored to specific industry needs. The company has already delivered over 40 AI projects to more than 30 clients. Established in 2020, Artificialy has made a leadership change, with its co-founder .

是一家设计和提供人工智能解决方案的人工智能公司，这些解决方案具有影响力、透明性，并且根据特定行业需求量身定制。该公司已经为超过30个客户交付了40多个AI项目。Artificialy成立于2020年，其联合创始人进行了领导层变更。

Luca Gambardella

卢卡·甘巴德拉

assuming the role of CEO. He will lead the startup through its growth phase by strengthening its presence in the Canton of Ticino and accelerating development at the national level.

假设首席执行官的角色。他将通过加强公司在提契诺州的存在和加速在全国范围的发展，带领这家初创公司度过其成长阶段。

(RAN)

(无线接入网)

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送